Literature DB >> 28114258

Melanoma Brain Metastases: Current Areas of Investigation and Future Directions.

Isabella Glitza Oliva1, Hussein Tawbi, Michael A Davies.   

Abstract

Metastases to the central nervous system (CNS) are one of the most common and lethal complications of metastatic melanoma. Historically, melanoma patients with CNS metastases have had dismal outcomes and very limited treatment options. However, the development of more effective targeted, immune, and radiation therapies is now leading to promising new investigations and strategies. Optimizing the development and testing of such strategies will benefit from an improved understanding of the unique molecular features of these tumors and the influence of the brain microenvironment. Accounting for unique clinical features and challenges of CNS metastases will also be critical to making significant clinical impact in patients.

Entities:  

Mesh:

Year:  2017        PMID: 28114258      PMCID: PMC5300745          DOI: 10.1097/PPO.0000000000000237

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  34 in total

1.  Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial.

Authors:  Georgina V Long; Uwe Trefzer; Michael A Davies; Richard F Kefford; Paolo A Ascierto; Paul B Chapman; Igor Puzanov; Axel Hauschild; Caroline Robert; Alain Algazi; Laurent Mortier; Hussein Tawbi; Tabea Wilhelm; Lisa Zimmer; Julie Switzky; Suzanne Swann; Anne-Marie Martin; Mary Guckert; Vicki Goodman; Michael Streit; John M Kirkwood; Dirk Schadendorf
Journal:  Lancet Oncol       Date:  2012-10-08       Impact factor: 41.316

2.  PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.

Authors:  Heike Niessner; Jennifer Schmitz; Ghazaleh Tabatabai; Andreas M Schmid; Carsten Calaminus; Tobias Sinnberg; Benjamin Weide; Thomas K Eigentler; Claus Garbe; Birgit Schittek; Leticia Quintanilla-Fend; Benjamin Bender; Marion Mai; Christian Praetorius; Stefan Beissert; Gabriele Schackert; Michael H Muders; Matthias Meinhardt; Gustavo B Baretton; Reinhard Dummer; Keith Flaherty; Bernd J Pichler; Dagmar Kulms; Dana Westphal; Friedegund Meier
Journal:  Clin Cancer Res       Date:  2016-06-15       Impact factor: 12.531

3.  Prognostic factors for survival in melanoma patients with brain metastases.

Authors:  Michael A Davies; Ping Liu; Susan McIntyre; Kevin B Kim; Nicholas Papadopoulos; Wen-Jen Hwu; Patrick Hwu; Agop Bedikian
Journal:  Cancer       Date:  2010-10-19       Impact factor: 6.860

4.  Successful treatment of melanoma brain metastases with adoptive cell therapy.

Authors:  Jenny J Hong; Steven A Rosenberg; Mark E Dudley; James C Yang; Donald E White; John A Butman; Richard M Sherry
Journal:  Clin Cancer Res       Date:  2010-08-18       Impact factor: 12.531

5.  Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study.

Authors:  Reinhard Dummer; Simone M Goldinger; Christian P Turtschi; Nina B Eggmann; Olivier Michielin; Lada Mitchell; Luisa Veronese; Paul René Hilfiker; Lea Felderer; Jeannine D Rinderknecht
Journal:  Eur J Cancer       Date:  2013-11-29       Impact factor: 9.162

Review 6.  Current treatment options of brain metastases and outcomes in patients with malignant melanoma.

Authors:  Jadwiga Nowak-Sadzikowska; Tomasz Walasek; Jerzy Jakubowicz; Paweł Blecharz; Marian Reinfuss
Journal:  Rep Pract Oncol Radiother       Date:  2015-12-29

7.  Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.

Authors:  Sarah B Goldberg; Scott N Gettinger; Amit Mahajan; Anne C Chiang; Roy S Herbst; Mario Sznol; Apostolos John Tsiouris; Justine Cohen; Alexander Vortmeyer; Lucia Jilaveanu; James Yu; Upendra Hegde; Stephanie Speaker; Matthew Madura; Amanda Ralabate; Angel Rivera; Elin Rowen; Heather Gerrish; Xiaopan Yao; Veronica Chiang; Harriet M Kluger
Journal:  Lancet Oncol       Date:  2016-06-03       Impact factor: 41.316

8.  Response of primary leptomeningeal melanoma to intrathecal recombinant interleukin-2. A case report.

Authors:  H M Fathallah-Shaykh; C Zimmerman; H Morgan; E Rushing; S C Schold; D H Unwin
Journal:  Cancer       Date:  1996-04-15       Impact factor: 6.860

9.  Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study.

Authors:  Masaaki Yamamoto; Toru Serizawa; Takashi Shuto; Atsuya Akabane; Yoshinori Higuchi; Jun Kawagishi; Kazuhiro Yamanaka; Yasunori Sato; Hidefumi Jokura; Shoji Yomo; Osamu Nagano; Hiroyuki Kenai; Akihito Moriki; Satoshi Suzuki; Yoshihisa Kida; Yoshiyasu Iwai; Motohiro Hayashi; Hiroaki Onishi; Masazumi Gondo; Mitsuya Sato; Tomohide Akimitsu; Kenji Kubo; Yasuhiro Kikuchi; Toru Shibasaki; Tomoaki Goto; Masami Takanashi; Yoshimasa Mori; Kintomo Takakura; Naokatsu Saeki; Etsuo Kunieda; Hidefumi Aoyama; Suketaka Momoshima; Kazuhiro Tsuchiya
Journal:  Lancet Oncol       Date:  2014-03-10       Impact factor: 41.316

10.  Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases.

Authors:  Heike Niessner; Andrea Forschner; Bernhard Klumpp; Jürgen B Honegger; Maria Witte; Antje Bornemann; Reinhard Dummer; Annemarie Adam; Jürgen Bauer; Ghazaleh Tabatabai; Keith Flaherty; Tobias Sinnberg; Daniela Beck; Ulrike Leiter; Cornelia Mauch; Alexander Roesch; Benjamin Weide; Thomas Eigentler; Dirk Schadendorf; Claus Garbe; Dagmar Kulms; Leticia Quintanilla-Martinez; Friedegund Meier
Journal:  Cancer Med       Date:  2013-02-03       Impact factor: 4.452

View more
  16 in total

Review 1.  Improving CNS Delivery to Brain Metastases by Blood-Tumor Barrier Disruption.

Authors:  Samuel A Sprowls; Tasneem A Arsiwala; Jacob R Bumgarner; Neal Shah; Sundus S Lateef; Brooke N Kielkowski; Paul R Lockman
Journal:  Trends Cancer       Date:  2019-07-20

2.  A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma.

Authors:  Clemens Krepler; Katrin Sproesser; Patricia Brafford; Marilda Beqiri; Bradley Garman; Min Xiao; Batool Shannan; Andrea Watters; Michela Perego; Gao Zhang; Adina Vultur; Xiangfan Yin; Qin Liu; Ioannis N Anastopoulos; Bradley Wubbenhorst; Melissa A Wilson; Wei Xu; Giorgos Karakousis; Michael Feldman; Xiaowei Xu; Ravi Amaravadi; Tara C Gangadhar; David E Elder; Lauren E Haydu; Jennifer A Wargo; Michael A Davies; Yiling Lu; Gordon B Mills; Dennie T Frederick; Michal Barzily-Rokni; Keith T Flaherty; Dave S Hoon; Michael Guarino; Joseph J Bennett; Randall W Ryan; Nicholas J Petrelli; Carol L Shields; Mizue Terai; Takami Sato; Andrew E Aplin; Alexander Roesch; David Darr; Steve Angus; Rakesh Kumar; Ensar Halilovic; Giordano Caponigro; Sebastien Jeay; Jens Wuerthner; Annette Walter; Matthias Ocker; Matthew B Boxer; Lynn Schuchter; Katherine L Nathanson; Meenhard Herlyn
Journal:  Cell Rep       Date:  2017-11-14       Impact factor: 9.423

3.  Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD).

Authors:  Sherise D Ferguson; Shivani Bindal; Roland L Bassett; Lauren E Haydu; Ian E McCutcheon; Amy B Heimberger; Jing Li; Barbara J O'Brien; Nandita Guha-Thakurta; Michael T Tetzlaff; Hussein Tawbi; Michael A Davies; Isabella C Glitza
Journal:  J Neurooncol       Date:  2019-03-07       Impact factor: 4.130

4.  Myelopathy from Intradural Extramedullary Metastasis as an Initial Presentation of Metastatic Melanoma.

Authors:  Alan A Stein; Gila R Weinstein; Colin Niezgoda; Sajeel Chowdhary; Frank Vrionis; John K Houten
Journal:  Cureus       Date:  2018-05-22

5.  Melanoma brain metastasis presentation, treatment, and outcomes in the age of targeted and immunotherapies.

Authors:  Evan D Bander; Melissa Yuan; Joseph A Carnevale; Anne S Reiner; Katherine S Panageas; Michael A Postow; Viviane Tabar; Nelson S Moss
Journal:  Cancer       Date:  2021-03-02       Impact factor: 6.921

6.  Inter-Tumor Heterogeneity-Melanomas Respond Differently to GM-CSF-Mediated Activation.

Authors:  Adi Moshe; Sivan Izraely; Orit Sagi-Assif; Sapir Malka; Shlomit Ben-Menachem; Tsipi Meshel; Metsada Pasmanik-Chor; Dave S B Hoon; Isaac P Witz
Journal:  Cells       Date:  2020-07-13       Impact factor: 6.600

Review 7.  Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma.

Authors:  Sunilkumar Kakadia; Naveen Yarlagadda; Ramez Awad; Madappa Kundranda; Jiaxin Niu; Boris Naraev; Lida Mina; Tomislav Dragovich; Mark Gimbel; Fade Mahmoud
Journal:  Onco Targets Ther       Date:  2018-10-17       Impact factor: 4.147

8.  Adjuvant radiotherapy and outcomes of presumed hemorrhagic melanoma brain metastases without malignant cells.

Authors:  Yuanxuan Xia; Leila A Mashouf; Russell Maxwell; Luke C Peng; Evan J Lipson; William H Sharfman; Chetan Bettegowda; Kristin J Redmond; Lawrence R Kleinberg; Michael Lim
Journal:  Surg Neurol Int       Date:  2018-07-26

9.  Microfibril-Associated Protein 2 (MFAP2) Potentiates Invasion and Migration of Melanoma by EMT and Wnt/β-Catenin Pathway.

Authors:  Zenghong Chen; Yang Lv; Dongsheng Cao; Xiaocan Li; Yuanyi Li
Journal:  Med Sci Monit       Date:  2020-05-28

10.  Meningeal lymphatic vessels regulate brain tumor drainage and immunity.

Authors:  Xueting Hu; Qiuping Deng; Lu Ma; Qingqing Li; Yidong Chen; Yuhan Liao; Fan Zhou; Chen Zhang; Linlin Shao; Jun Feng; Tubao He; Weihai Ning; Yan Kong; Yingqing Huo; Aibin He; Bing Liu; Jingjing Zhang; Ralf Adams; Yulong He; Fuchou Tang; Xiuwu Bian; Jincai Luo
Journal:  Cell Res       Date:  2020-02-24       Impact factor: 25.617

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.